Avidity Biosciences to Participate in Upcoming Investor Conference

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA), a biopharmaceutical company developing Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in an upcoming investor conference. The company's management will be present at the Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. PT / 10:30 a.m. ET.

A live webcast of the event will be available, along with up-to-date details and an archived replay, on the 'Events and Presentations' page in the 'Investors' section of Avidity's website. Interested parties can access this information at https://aviditybiosciences.investorroom.com/events-and-presentations.

SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:

• Chardan 8^th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. PT / 10:30 a.m. ET

A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Mike MacLean
(619) 837-5014
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302257800.html

SOURCE Avidity Biosciences, Inc.

FAQ

When is Avidity Biosciences (RNA) participating in the Chardan Genetic Medicines Conference?

Avidity Biosciences (RNA) is participating in the Chardan 8th Annual Genetic Medicines Conference on October 1 at 7:30 a.m. PT / 10:30 a.m. ET.

Where can I find the webcast for Avidity Biosciences' (RNA) presentation at the Chardan conference?

The live webcast and archived replay of Avidity Biosciences' (RNA) presentation will be available on the 'Events and Presentations' page in the 'Investors' section of their website at https://aviditybiosciences.investorroom.com/events-and-presentations.

What type of RNA therapeutics is Avidity Biosciences (RNA) developing?

Avidity Biosciences (RNA) is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™).

What is the stock symbol for Avidity Biosciences?

The stock symbol for Avidity Biosciences is RNA, and it is listed on the Nasdaq stock exchange.